TABLE 3.
Clinical course of patients with ulcerative colitis according to distribution of lesions
|
Distribution
|
P | ||
|---|---|---|---|
| Typical (n=194) | Atypical (n=46) | ||
| Duration of clinical follow-up, months* | 66 (1–139) | 69 (2–138) | 0.108 |
| Treatment during follow-up 5-ASA (topical and/or oral) | 194 (100) | 46 (100) | |
| Systemic corticosteroids | 68 (35.1) | 15 (32.6) | 0.864 |
| Azathioprine/6-mercaptopurine | 10 (5.2) | 5 (10.9) | 0.173 |
| Infliximab | 2 (1.0) | 0 (0.0) | 1.000 |
| Initial remission rate | 193 (99.5) | 46 (100.0) | 1.000 |
| Cumulative rate of disease relapse, % | 0.368 | ||
| 1-year relapse rate | 34.8 | 50.5 | |
| 3-year relapse rate | 60.2 | 66.1 | |
| 5-year relapse rate | 72.6 | 80.9 | |
| Total proctocolectomy | 2 (1.0) | 2 (4.3) | 0.167 |
| Mortality | 3 (1.5) | 1 (2.2) | 0.576 |
Data presented as n (%) unless otherwise indicated.
*
Data presented as median (range). 5-ASA 5-aminosalicylic acid